Nov 30, 2021 PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study
Nov 12, 2021 PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation
Sep 21, 2021 PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests
Sep 8, 2021 PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
Aug 31, 2021 PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study
Aug 25, 2021 PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise
Aug 23, 2021 PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Aug 19, 2021 PharmaCyte Biotech Announces $70 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
